|
Dynavax starts Phase I trial of asthma treatment
San Francisco Business Times (blog) The Berkeley company (NASDAQ: DVAX) will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo. If all goes well, … DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human … Dynavax Initiates First Human Trial in Asthma Program |
View full post on asthma – Google News